Aytu BioPharma (AYTU) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AYTU Stock Forecast

Aytu BioPharma stock forecast is as follows:

Aytu BioPharma Financial Forecast

Aytu BioPharma Revenue Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
Revenue	-	-	-	-	-	-	$22.93M	$22.10M	$30.73M	$22.73M	$26.28M	$27.66M	$27.45M	$24.20M	$23.13M	$21.90M	$23.48M	$13.48M	$15.15M	$13.52M	$14.86M	$8.16M	$3.18M	$1.44M	$1.72M	$2.38M	$607.00K	$894.00K	$698.00K
Avg Forecast	$20.63M	$17.59M	$15.55M	$13.77M	$18.30M	$17.35M	$21.75M	$27.73M	$27.69M	$28.00M	$29.50M	$24.30M	$25.70M	$24.20M	$23.10M	$22.10M	$24.70M	$14.03M	$12.25M	$13.33M	$11.24M	$5.81M	$2.74M	$2.02M	$1.77M	$2.04M	$7.53M	$679.88K	$635.68K
High Forecast	$20.63M	$17.59M	$15.55M	$13.77M	$18.30M	$17.35M	$21.75M	$27.73M	$27.69M	$28.00M	$29.50M	$24.30M	$25.70M	$24.20M	$23.10M	$22.10M	$24.70M	$14.03M	$12.25M	$13.33M	$11.24M	$5.81M	$2.74M	$2.02M	$1.77M	$2.04M	$9.04M	$815.85K	$762.81K
Low Forecast	$20.63M	$17.59M	$15.55M	$13.77M	$18.30M	$17.35M	$21.75M	$27.73M	$27.69M	$28.00M	$29.50M	$24.30M	$25.70M	$24.20M	$23.10M	$22.10M	$24.70M	$14.03M	$12.25M	$13.33M	$11.24M	$5.81M	$2.74M	$2.02M	$1.77M	$2.04M	$6.02M	$543.90K	$508.54K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	13	13	13	13	15	7	18
Surprise %	-	-	-	-	-	-	1.05%	0.80%	1.11%	0.81%	0.89%	1.14%	1.07%	1.00%	1.00%	0.99%	0.95%	0.96%	1.24%	1.01%	1.32%	1.40%	1.16%	0.71%	0.97%	1.17%	0.08%	1.31%	1.10%

Aytu BioPharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $17.35M, with a low forecast of $17.35M, and a high forecast of $17.35M. AYTU's average Quarter revenue forecast represents a -24.37% decrease compared to the company's last Quarter revenue of $22.93M (Dec 23).

Aytu BioPharma EBITDA Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	13	13	13	13	15	7	18
EBITDA	-	-	-	-	-	-	$2.36M	$-1.50M	$8.02M	$-9.19M	$-819.00K	$803.00K	$3.56M	$36.76M	$-8.34M	$14.10M	$-5.19M	$-7.30M	$-83.61K	$-1.47M	$-8.69M	$-3.17M	$-8.88M	$-3.87M	$5.99M	$-3.55M	$-3.25M	$-4.32M	$-5.14M
Avg Forecast	$-5.03M	$-4.29M	$-3.79M	$-3.36M	$-4.46M	$-93.85M	$-5.30M	$-6.76M	$-6.75M	$-100.38M	$-10.30M	$-3.31M	$-3.50M	$-107.36M	$-3.15M	$-3.01M	$-3.37M	$-43.97M	$-1.67M	$-1.82M	$-1.53M	$-4.89M	$-373.22K	$-274.71K	$-241.99K	$-4.27M	$-3.40M	$-3.17M	$-2.72M
High Forecast	$-5.03M	$-4.29M	$-3.79M	$-3.36M	$-4.46M	$-75.08M	$-5.30M	$-6.76M	$-6.75M	$-80.30M	$-8.24M	$-3.31M	$-3.50M	$-85.89M	$-3.15M	$-3.01M	$-3.37M	$-35.18M	$-1.67M	$-1.82M	$-1.53M	$-3.91M	$-373.22K	$-274.71K	$-241.99K	$-3.42M	$-2.72M	$-2.54M	$-2.18M
Low Forecast	$-5.03M	$-4.29M	$-3.79M	$-3.36M	$-4.46M	$-112.63M	$-5.30M	$-6.76M	$-6.75M	$-120.46M	$-12.36M	$-3.31M	$-3.50M	$-128.83M	$-3.15M	$-3.01M	$-3.37M	$-52.77M	$-1.67M	$-1.82M	$-1.53M	$-5.87M	$-373.22K	$-274.71K	$-241.99K	$-5.12M	$-4.08M	$-3.81M	$-3.27M
Surprise %	-	-	-	-	-	-	-0.45%	0.22%	-1.19%	0.09%	0.08%	-0.24%	-1.02%	-0.34%	2.65%	-4.68%	1.54%	0.17%	0.05%	0.81%	5.67%	0.65%	23.79%	14.08%	-24.74%	0.83%	0.96%	1.36%	1.89%

1 analysts predict AYTU's average Quarter EBITDA for Mar 24 to be $-93.85M, with a high of $-75.08M and a low of $-112.63M. This is -4070.17% lower than Aytu BioPharma's previous annual EBITDA (Dec 23) of $2.36M.

Aytu BioPharma Net Income Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	13	13	13	13	15	7	18
Net Income	-	-	-	-	-	-	$-220.00K	$-8.12M	$-2.46M	$-5.84M	$-10.39M	$-4.24M	$-38.06M	$-140.25M	$-11.55M	$-27.85M	$-19.00M	$-37.33M	$-9.53M	$-5.05M	$4.87M	$-5.33M	$-214.25K	$-5.12M	$-34.30M	$-4.70M	$-2.82M	$-5.22M	$-5.07M
Avg Forecast	$4.37M	$1.36M	$-545.98K	$-3.09M	$-4.09M	$-98.79M	$-2.27M	$-363.98K	$-8.64M	$-105.66M	$-13.40M	$-20.23M	$-26.98M	$-113.01M	$-49.46M	$-55.08M	$-46.08M	$-58.39M	$-49.46M	$-61.82M	$-39.34M	$-7.03M	$-286.62M	$-309.10M	$-370.92M	$-5.12M	$-4.87M	$-3.60M	$-3.48M
High Forecast	$4.37M	$1.36M	$-545.98K	$-3.09M	$-4.09M	$-79.03M	$-2.27M	$-363.98K	$-8.64M	$-84.53M	$-10.72M	$-20.23M	$-26.98M	$-90.41M	$-49.46M	$-55.08M	$-46.08M	$-46.71M	$-49.46M	$-61.82M	$-39.34M	$-5.62M	$-286.62M	$-309.10M	$-370.92M	$-4.09M	$-3.89M	$-2.88M	$-2.78M
Low Forecast	$4.37M	$1.36M	$-545.98K	$-3.09M	$-4.09M	$-118.55M	$-2.27M	$-363.98K	$-8.64M	$-126.79M	$-16.08M	$-20.23M	$-26.98M	$-135.61M	$-49.46M	$-55.08M	$-46.08M	$-70.07M	$-49.46M	$-61.82M	$-39.34M	$-8.43M	$-286.62M	$-309.10M	$-370.92M	$-6.14M	$-5.84M	$-4.33M	$-4.17M
Surprise %	-	-	-	-	-	-	0.10%	22.31%	0.28%	0.06%	0.78%	0.21%	1.41%	1.24%	0.23%	0.51%	0.41%	0.64%	0.19%	0.08%	-0.12%	0.76%	0.00%	0.02%	0.09%	0.92%	0.58%	1.45%	1.46%

Aytu BioPharma's average Quarter net income forecast for Sep 20 is $-61.82M, with a range of $-61.82M to $-61.82M. AYTU's average Quarter net income forecast represents a -1369.80% decrease compared to the company's last Quarter net income of $4.87M (Jun 20).

Aytu BioPharma SG&A Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	13	13	13	13	15	7	18
SG&A	-	-	-	-	-	-	$12.02M	$14.38M	$14.10M	$19.98M	$18.58M	$17.42M	$17.40M	$17.36M	$17.61M	$17.51M	$19.98M	$12.85M	$12.85M	$11.49M	$13.64M	$9.50M	$6.52M	$5.15M	$4.90M	$5.38M	$4.64M	$4.42M	$5.76M
Avg Forecast	$16.90M	$14.41M	$12.74M	$11.28M	$14.99M	$14.21M	$17.81M	$22.71M	$22.69M	$22.94M	$20.44M	$19.91M	$21.05M	$19.82M	$18.92M	$18.10M	$20.23M	$11.50M	$10.04M	$10.92M	$9.21M	$4.76M	$2.24M	$1.65M	$1.45M	$1.67M	$6.17M	$556.95K	$520.74K
High Forecast	$16.90M	$14.41M	$12.74M	$11.28M	$14.99M	$14.21M	$17.81M	$22.71M	$22.69M	$22.94M	$24.53M	$19.91M	$21.05M	$19.82M	$18.92M	$18.10M	$20.23M	$11.50M	$10.04M	$10.92M	$9.21M	$4.76M	$2.24M	$1.65M	$1.45M	$1.67M	$7.40M	$668.33K	$624.89K
Low Forecast	$16.90M	$14.41M	$12.74M	$11.28M	$14.99M	$14.21M	$17.81M	$22.71M	$22.69M	$22.94M	$16.35M	$19.91M	$21.05M	$19.82M	$18.92M	$18.10M	$20.23M	$11.50M	$10.04M	$10.92M	$9.21M	$4.76M	$2.24M	$1.65M	$1.45M	$1.67M	$4.94M	$445.56K	$416.59K
Surprise %	-	-	-	-	-	-	0.67%	0.63%	0.62%	0.87%	0.91%	0.88%	0.83%	0.88%	0.93%	0.97%	0.99%	1.12%	1.28%	1.05%	1.48%	2.00%	2.91%	3.12%	3.37%	3.22%	0.75%	7.94%	11.05%

Aytu BioPharma's average Quarter SG&A projection for Mar 24 is $14.21M, based on 1 Wall Street analysts, with a range of $14.21M to $14.21M. The forecast indicates a 18.27% rise compared to AYTU last annual SG&A of $12.02M (Dec 23).

Aytu BioPharma EPS Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9	9	13	13	13	13	15	7	18
EPS	-	-	-	-	-	-	-	$-1.48	$-0.59	$-1.57	$-3.34	$-33.66	$-21.16	$-94.48	$-8.74	$-21.76	$-16.15	$-41.27	$-25.67	$-8.31	$8.59	$-33.29	$111.05	$-66.83	$-1.12	$-103.64	$-517.64	$-31.93K	$-80.43K
Avg Forecast	$0.48	$0.15	$-0.06	$-0.34	$-0.45	$-0.64	$-0.25	$-0.04	$-0.95	$-0.63	$-0.70	$-3.60	$-4.80	$-22.00	$-8.80	$-9.80	$-8.20	$-6.67	$-8.80	$-11.00	$-7.00	$-10.00	$-51.00	$-55.00	$-66.00	$-116.00	$-34.54	$-101.34	$-204.00
High Forecast	$0.48	$0.15	$-0.06	$-0.34	$-0.45	$-0.64	$-0.25	$-0.04	$-0.95	$-0.63	$-0.70	$-3.60	$-4.80	$-22.00	$-8.80	$-9.80	$-8.20	$-6.67	$-8.80	$-11.00	$-7.00	$-10.00	$-51.00	$-55.00	$-66.00	$-116.00	$-27.63	$-81.07	$-163.20
Low Forecast	$0.48	$0.15	$-0.06	$-0.34	$-0.45	$-0.64	$-0.25	$-0.04	$-0.95	$-0.63	$-0.70	$-3.60	$-4.80	$-22.00	$-8.80	$-9.80	$-8.20	$-6.67	$-8.80	$-11.00	$-7.00	$-10.00	$-51.00	$-55.00	$-66.00	$-116.00	$-41.45	$-121.61	$-244.80
Surprise %	-	-	-	-	-	-	-	37.00%	0.62%	2.49%	4.77%	9.35%	4.41%	4.29%	0.99%	2.22%	1.97%	6.19%	2.92%	0.76%	-1.23%	3.33%	-2.18%	1.22%	0.02%	0.89%	14.99%	315.09%	394.25%

According to 9 Wall Street analysts, Aytu BioPharma's projected average Quarter EPS for Sep 20 is $-11.00, with a low estimate of $-11.00 and a high estimate of $-11.00. This represents a -228.06% decrease compared to AYTU previous annual EPS of $8.59 (Jun 20).

Aytu BioPharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
FLGC	Flora Growth	$1.31	$173.50	13144.27%	Hold
ESPR	Esperion Therapeutics	$2.10	$16.00	661.90%	Buy
AYTU	Aytu BioPharma	$1.55	$11.00	609.68%	-
EVOK	Evoke Pharma	$4.37	$18.00	311.90%	Buy
IRWD	Ironwood Pharmaceuticals	$4.11	$11.67	183.94%	Buy
AQST	Aquestive Therapeutics	$4.57	$10.25	124.29%	Buy
AVDL	Avadel Pharmaceuticals	$11.59	$17.80	53.58%	Buy
ALIM	Alimera Sciences	$5.54	$5.75	3.79%	Hold
LFCR	Lifecore Biomedical	$6.68	$6.50	-2.69%	Buy
GHSI	Guardion Health Sciences	$3.22	$0.01	-99.69%	Buy

AYTU Forecast FAQ

What are Aytu BioPharma's analysts' financial forecasts?

Aytu BioPharma's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $85.12M (high $85.12M, low $85.12M), average EBITDA is $-110M (high $-91.602M, low $-129M), average net income is $-106M (high $-85.768M, low $-125M), average SG&A $69.73M (high $69.73M, low $69.73M), and average EPS is $-1.38 (high $-1.38, low $-1.38). AYTU's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $67.54M (high $67.54M, low $67.54M), average EBITDA is $-16.461M (high $-16.461M, low $-16.461M), average net income is $2.09M (high $2.09M, low $2.09M), average SG&A $55.33M (high $55.33M, low $55.33M), and average EPS is $0.23 (high $0.23, low $0.23).

Did the AYTU's actual financial results beat the analysts' financial forecasts?

Based on Aytu BioPharma's last annual report (Jun 2022), the company's revenue was $96.67M, beating the average analysts forecast of $95.1M by 1.65%. Apple's EBITDA was $41.28M, missing the average prediction of $-117M by -135.28%. The company's net income was $-110M, missing the average estimation of $-245M by -54.94%. Apple's SG&A was $69.88M, missing the average forecast of $77.9M by -10.30%. Lastly, the company's EPS was $-74.95, beating the average prediction of $-45.4 by 65.09%. In terms of the last quarterly report (Dec 2023), Aytu BioPharma's revenue was $22.93M, beating the average analysts' forecast of $21.74M by 5.47%. The company's EBITDA was $2.36M, missing the average prediction of $-5.3M by -144.61%. Aytu BioPharma's net income was $-220K, missing the average estimation of $-2.275M by -90.33%. The company's SG&A was $12.02M, missing the average forecast of $17.81M by -32.55%. Lastly, the company's EPS was $0, missing the average prediction of $-0.25 by -100.00%